Trial intelligence / Profile preview

Hetrombopag for chemotherapy-induced thrombocytopenia in gastrointestinal tumors

ChiCTR2100053155Phase 4Not yet recruiting

Sponsor
Shanxi Cancer Hospital
Start
Dec 2021
Modality
Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of hetrombopag in Thrombocytopenia, sponsored by Shanxi Cancer Hospital. Primary endpoint: Platelet index. Planned start Dec 2021; status: not yet recruiting.

02

Drugs

hetrombopag
03

Conditions

Thrombocytopenia

Beyond the preview

Go deeper on ChiCTR2100053155.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2100053155.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call